Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANKTIVA + BCG vs BCG in NMIBC
NCT07551544Phase 3Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- May 2026
- Primary completion
- May 2032
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
01
Overview
Phase 3, randomised, open-label trial of nogapendekin alfa inbakicept in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by ImmunityBio, Inc. Primary endpoints: Clinical Complete Response Rate at 7 weeks and Disease Free Survival at 36 months. Planned start May 2026; status: withdrawn.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07551544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07551544.